Kures, Inc.

An atai Life Sciences subsidiary and Columbia University spinout, Kures developed KUR-101—a deuterated mitragynine derivative from the kratom plant—as a safer opioid receptor modulator for acute pain and opioid use disorder, with a second asset KUR-002 targeting depression. The Phase 1 trial of KUR-101 in healthy adults demonstrated safety and tolerability with no severe adverse events, advancing a kratom-derived mechanism distinct from conventional opioids.